Reverse gene therapy
US6852704B1 · kind B1 · utility
3Cited by
5References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2000 |
| Grant date | Feb 8, 2005 |
| Priority date | — |
| Expiry date | Oct 8, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/005
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.